Avecho BiotechnologyASX:AVE Piotroski F-Score is 6 as of Jul. 06, 2026, which is 50% above its 10-year median of 4.00. The stock has 2 warning signs investors should review. Among 1,332 Biotechnology companies, Avecho Biotechnology ranks better than 91.97% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Avecho Biotechnology has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Avecho Biotechnology's Piotroski F-Score or its related term are showing as below:
ASX:AVE'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 4 Max: 8
Current: 6
During the past 13 years, the highest Piotroski F-Score of Avecho Biotechnology was 8. The lowest was 1. And the median was 4.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Avecho Biotechnology Piotroski F-Score Related Terms
Avecho Biotechnology Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Avecho Biotechnology's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AVE vs VRTX, REGN, ALNY: Piotroski F-Score Comparison
For the Biotechnology subindustry, Avecho Biotechnology's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avecho Biotechnology Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Avecho Biotechnology's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Avecho Biotechnology's current Net Income (TTM) was -4.42.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Avecho Biotechnology's return on assets of this year was -0.88393036. Avecho Biotechnology's return on assets of last year was -0.42563054.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Avecho Biotechnology's gearing of this year was 0. Avecho Biotechnology's gearing of last year was 0.00227052.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Avecho Biotechnology's current ratio of this year was 9.95345557. Avecho Biotechnology's current ratio of last year was 2.8128655.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Avecho Biotechnology's number of shares in issue this year was 3266.774. Avecho Biotechnology's number of shares in issue last year was 3169.297.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Avecho Biotechnology's gross margin of this year was 0.71967871. Avecho Biotechnology's gross margin of last year was 0.59311562.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Avecho Biotechnology's asset turnover of this year was 0.24914949. Avecho Biotechnology's asset turnover of last year was 0.15446489.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
1
+
0
+
1
+
1
+
1
+
0
+
1
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Avecho Biotechnology has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Avecho Biotechnology (ASX:AVE) has a Piotroski F-Score of 6 as of Jul. 06, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Avecho Biotechnology and its competitors. This is 50% above median its historical median of 4.00. Over the past decade, Avecho Biotechnology's Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, Avecho Biotechnology ranks #107 out of 1332 companies in the Biotechnology industry, placing it in the top 8%.
Is Avecho Biotechnology's Piotroski F-Score too high?
Avecho Biotechnology's current Piotroski F-Score of 6 is 50% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Biotechnology industry median Piotroski F-Score is 3.00. Avecho Biotechnology's value of 6 is 100% above this industry median. Based on the distribution chart, Avecho Biotechnology ranks #107 out of 1332 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Avecho Biotechnology's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avecho Biotechnology ranks #107 out of 1332 companies for Piotroski F-Score. This places Avecho Biotechnology in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Avecho Biotechnology's value of 6 is 100% above this benchmark. Historically, Avecho Biotechnology's own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Avecho Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,332 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avecho Biotechnology's current Piotroski F-Score of 6 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Avecho Biotechnology and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avecho Biotechnology's current Piotroski F-Score is 6, which is 50% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (ASX:AVE) has a current Piotroski F-Score of 6. The current Piotroski F-Score is 6, which is 50% above median its 10-year median of 4.00 and 100% above the Biotechnology industry median of 3.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Avecho Biotechnology (ASX:AVE), the current Piotroski F-Score is 6 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVE has been successfully added to your 